What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? - Cassava Sciences ( NASDAQ:SAVA )

a week ago

Last month, Cassava Sciences Inc. SAVA agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company's controversial Alzheimer's drug, simufilam. The SEC also charged Hoau-Yan Wang, a consultant and co-developer of the drug, with ...

Ticker	Sentiment	Impact
SAVA	Neutral	37 %